These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 24133374)

  • 1. Phosphate control in dialysis.
    Cupisti A; Gallieni M; Rizzo MA; Caria S; Meola M; Bolasco P
    Int J Nephrol Renovasc Dis; 2013 Oct; 6():193-205. PubMed ID: 24133374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The contribution of dialysis and laboratoristic methods for the control of phosphates].
    Bolasco P
    G Ital Nefrol; 2014; 31(2):. PubMed ID: 24777923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphate control in chronic uremia: don't forget diet.
    Cupisti A; Morelli E; D'Alessandro C; Lupetti S; Barsotti G
    J Nephrol; 2003; 16(1):29-33. PubMed ID: 12649532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary Phosphate and the Forgotten Kidney Patient: A Critical Need for FDA Regulatory Action.
    Calvo MS; Sherman RA; Uribarri J
    Am J Kidney Dis; 2019 Apr; 73(4):542-551. PubMed ID: 30686528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The "phosphorus pyramid": a visual tool for dietary phosphate management in dialysis and CKD patients.
    D'Alessandro C; Piccoli GB; Cupisti A
    BMC Nephrol; 2015 Jan; 16():9. PubMed ID: 25603926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of natural and added dietary phosphorus burden in kidney disease.
    Cupisti A; Kalantar-Zadeh K
    Semin Nephrol; 2013 Mar; 33(2):180-90. PubMed ID: 23465504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperphosphataemia: treatment options.
    Malberti F
    Drugs; 2013 May; 73(7):673-88. PubMed ID: 23625273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
    Malberti F
    G Ital Nefrol; 2010; 27 Suppl 52():S47-54. PubMed ID: 21132662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ; González EA
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperphosphatemia in Dialysis Patients: Beyond Nonadherence to Diet and Binders.
    Sherman RA
    Am J Kidney Dis; 2016 Feb; 67(2):182-6. PubMed ID: 26508681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily dietary phosphorus intake variability and hemodialysis patient adherence to phosphate binder therapy.
    Tao X; Zhang H; Yang Y; Zhang C; Wang M
    Hemodial Int; 2019 Oct; 23(4):458-465. PubMed ID: 31328873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphate Intake and Removal in Predominantly Vegetarian Patients on Twice-Weekly Hemodialysis.
    Rao NS; Chandra A; Kulshreshta M; Tiwari P; Saran S; Lohiya A
    Indian J Nephrol; 2022; 32(6):582-587. PubMed ID: 36704595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphate removal and hemodialysis conditions.
    Pohlmeier R; Vienken J
    Kidney Int Suppl; 2001 Feb; 78():S190-4. PubMed ID: 11169009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of hyperphosphatemia.
    Kuhlmann MK
    Hemodial Int; 2006 Oct; 10(4):338-45. PubMed ID: 17014508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.
    Lorenzo Sellares V; Torres Ramírez A
    Drugs Aging; 2004; 21(3):153-65. PubMed ID: 14979734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Most consumed processed foods by patients on hemodialysis: Alert for phosphate-containing additives and the phosphate-to-protein ratio.
    Watanabe MT; Araujo RM; Vogt BP; Barretti P; Caramori JCT
    Clin Nutr ESPEN; 2016 Aug; 14():37-41. PubMed ID: 28531397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.